PDF
ePub
Citation
Print
Abstract
Purpose
This study aimed to investigate the effects of vasopressin and desmopressin on the contractile and relaxative responses of rabbit cavernosal smooth muscle.
Materials and Methods
Isometric tension studies were conducted to investigate the effects of vasopressin (10−14-10−8M) and desmopressin (10−14-10−8M) on the contraction and relaxation responses of rabbits cavernous muscle strips in an organ bath. The effects of pretreatment with phenylephrine (10−5M), L-NAME (10−5M) and indomethacin (10−5M) on the contraction and relaxation responses of the vasopressin and desmopressin were also investigated. The statistics were analyzed by Student's t-test and ANOVA.
Results
Vasopressin contracted the strips in a dose-dependent manner, while desmopressin did not. The phenylephrine-induced contraction was dose-dependently increased by vasopressin, but it was dose-dependently relaxed by desmopressin. L-NAME pre-treatment did not block the relaxation response, but indomethacin pre-treatment did. Vasopressin-induced contraction occurred the via V1 receptor, while desmopressin induced relaxation occurred via the V2 receptor.
REFERENCES
1.Goldsmith SR. Vasopressin: a therapeutic target in congestive heart failure? J Card Fail. 1999. 5:347–56.
2.Walker BR., Childs ME., Adams EM. Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors. Am J Physiol. 1988. 255:H261–5.
3.Nam SG., Moon DG., Kim JJ. Efficacy of desmopressin in treatment of adult nocturia. Korean J Urol. 2004. 45:49–55.
4.Ostrowski NL., Young WS 3rd., Knepper MA., Lolait SJ. Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats. Endocrinology. 1993. 133:1849–59.
5.Ostrowski NL., Lolait SJ., Bradley DJ., O'Carroll AM., Brown-stein MJ., Young WS 3rd. Distribution of V1a and V2 vasopressin receptor messenger ribonucleic acids in rat liver, kidney, pituitary and brain. Endocrinology. 1992. 131:533–5.
6.Fernández N., Martínez MA., García-Villalón AL., Monge L., Diéguez G. Cerebral vasoconstriction produced by vasopressin in conscious goats: role of vasopressin V (1) and V (2) receptors and nitric oxide. Br J Pharmacol. 2001. 132:1837–44.
7.Penit J., Faure M., Jard S. Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture. Am J Physiol. 1983. 244:E72–82.
8.Martínez MC., Vila JM., Aldasoro M., Medina P., Flor B., Lluch S. Relaxation of human isolated mesenteric arteries by vasopressin and desmopressin. Br J Pharmacol. 1994. 113:419–24.
9.Michell RH., Kirk CJ., Billah MM. Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans. 1979. 7:861–5.
10.Medina P., Vila JM., Martinez MC., Aldasoro M., Chuan P., Lluch S. Effects of vasopressin on human renal arteries. Eur J Clin Invest. 1996. 26:966–72.
11.Vargiu R., Usai P., De Lisa A., Argiolas A., Scarpa RM., Gessa GL, et al. Vasopressin excitatory action on smooth muscle from human renal calyx and pelvis. Pharmacol Res. 2004. 50:617–22.
12.Medina P., Segarra G., Chuan P., Domenech C., Vila JM., Aldasoro M, et al. Vasopressin receptors involved in adrenergic neurotransmission in the circular muscle of the human vas deferens. Eur J Pharmacol. 1998. 355:41–9.
13.Xu YJ., Gopalakrishnan V. Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ Res. 1991. 69:239–45.
14.Landry DW., Levin HR., Gallant EM., Ashton RC Jr., Seo S., D'Alessandro D, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997. 95:1122–5.
15.Udelson JE., Smith WB., Hendrix GH., Painchaud CA., Ghazzi M., Thomas I, et al. Acute hemodynamic effects of conivaptan, a dual V (1A) and V (2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001. 104:2417–23.
16.Bichet DG., Razi M., Lonergan M., Arthus MF., Papukna V., Kortas C, et al. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med. 1988. 318:881–7.
17.Sawyer WH., Acosta M., Manning M. Structural changes in the arginine vasopressin molecule that prolong its antidiuretic action. Endocrinology. 1974. 95:140–9.
18.van Lieburg AF., Knoers NV., Monnens LA., Smits P. Effects of arginine vasopressin and 1-desamino-8-D arginine vasopressin on forearm vasculature of healthy subjects and patients with a V2 receptor defect. J Hypertens. 1995. 13:1695–700.
19.Martinez MC., Aldasoro M., Vila JM., Medina P., Lluch S. Responses to vasopressin and desmopressin of human cerebral arteries. J Pharmacol Exp Ther. 1994. 270:622–7.
20.Medina P., Segarra G., Vila JM., Chuan P., Domenech C., Lluch S. V2-receptor-mediated relaxation of human renal arteries in response to desmopressin. Am J Hypertens. 1999. 12:188–93.
21.Medina P., Martínez MC., Aldasoro M., Vila JM., Chuan P., Lluch S. Contractile responses of human deferential artery and vas deferens to vasopressin. Eur J Pharmacol. 1996. 300:221–5.
22.Segarra G., Medina P., Domenech C., Vila JM., Martinez-Leon JB., Aldasoro M, et al. Role of vasopressin on adrenergic neurotransmission in human penile blood vessels. J Pharmacol Exp Ther. 1998. 286:1315–20.
23.Aldasoro M., Medina P., Vila JM., Otero E., Martinez-León JB., Lluch S. Endothelium-dependent relaxation of human saphenous veins in response to vasopressin and desmopressin. J Vasc Surg. 1997. 25:696–703.
24.Giuliano F., Bernabe J., Jardin A., Rousseau JP. Antierectile role of the sympathetic nervous system in rats. J Urol. 1993. 150:519–24.
25.Andersson KE., Fovaeus M., Hedlund H., Lundin S. Characterization of immunoreactive arginine vasopressin (AVP) in and effects of AVP on isolated human penile erectile tissues. J Urol. 1987. 137:1278–82.
26.Hedlund H., Andersson KE. Effects of some peptides on isolated human penile erectile tissue and cavernous artery. Acta Physiol Scand. 1985. 124:413–9.
27.Simon J., Kasson BG. Identification of vasopressin mRNA in rat aorta. Hypertension. 1995. 25:1030–3.
28.Nielsen S., Chou CL., Marples D., Christensen EI., Kishore BK., Knepper MA. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA. 1995. 92:1013–7.
29.Rees DD., Palmer RM., Schulz R., Hodson HF., Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol. 1990. 101:746–52.
30.Becker AJ., Uckert S., Ness BO., Stief CG., Scheller F., Knapp WH, et al. Systemic and cavernous plasma levels of vasopressin in healthy males during different functional conditions of the penis. Urol Res. 2003. 31:66–9.
Fig. 1.
Effects of vasopressin and desmopressin on rabbit corpus cavernosal strips. The vasopressin contracts the strips in a dose-dependent manner, but the desmopressin does not contract the strips.
Fig. 2.
Effects of vasopressin and desmopressin on phenylephrine (10−5M) pre-treated cavernosal smooth muscle strips. Vasopressin contracts the rabbit corpus cavernous the strips in a dose-dependent manner, but in contrast, desmopressin relaxes the rabbit corpus cavernous strips.
Fig. 3.
Desmopressin relaxes the phenylephrine pre-treated corpus cavernosal smooth muscle strips in a dose-dependent manner (control group: phenylephrine, desmopressin). Yet, L-NAME (10−5 M) pre-treatment did not block the relaxations (L-NAME pretreatment: L-NAME, phenylephrine, desmopressin).
Fig. 4.
Desmopressin relaxes the phenylephrine pre-treated corpus cavernosal smooth muscle strips in a dose-dependent manner (control group: phenylephrine, desmopressin). Yet, indomethacin (10−5M) pre-treatment inhibits the desmopressin induced-relaxations (Indomethacin pretreatment: indomethacin, phenylephrine, desmopressin) (*: p＜0.05).
XML Download